The decision applies to adolescents and adults and aligns with earlier US authorization for higher-risk groups.

Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to support financial flexibility and ...

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...

In the third quarter, our revenue were $1 billion, driven by sales of our fully approved vaccines, Spikevax, mNEXSPIKE, ...